1.Effect of Acupoint Application withBaoshen Cataplasm on the Quality of Life in Patients with Chronic Kidney Diseases
Yuanming BA ; Jing XIA ; Chengyin LI
Shanghai Journal of Acupuncture and Moxibustion 2015;(2):113-116
ObjectiveTo observe the clinical efficacy of acupoint application withBaoShen cataplasm in treating chronic kidney diseases (CKD) and its effect on the quality of life.MethodSixty CKD patients were randomized into a treatment group and control group, 30 cases in each group. The control group was intervened by conventional Western medicine, while the treatment group was by acupoint application withBaoshen cataplasm in addition to the same Western medicine treatment. The SF-36, symptom score and Chinese medicine, 24hupq, Scr, and GFR were observed before and after intervention.Result The total effective rate was 86.7% in the treatment group versus 66.7% in the control group, and the difference was statistically significant (P<0.05); in the treatment group, the effective rates for the kidney yang deficiency and kidney yin deficiency were respectively 88.2% and 84.6%, versus 68.8% and 64.3% in the control group, and the differences were statistically significant (P<0.05); the symptom score of Chinese medicine dropped significantly in both groups after intervention (P<0.05), while the change in the treatment group was more marked than that in the control group (P<0.05); after intervention, the Scr and 24hupq decreased and GFR increased significantly in both groups (P<0.05); the bodily pain, general health, vitality, social function, emotional role and mental health scored higher after intervention in both groups, and the scores in the treatment group were significantly higher than that in the control group (P<0.05).ConclusionAcupoint Application withBaoshen cataplasm can significantly improve the renal function and symptoms of CKD patients, promote the quality of life, and it can produce a content therapeutic efficacy in treating CKD due to kidney yang deficiency and kidney yin deficiency based on the conventional treatment.
2.Preparation of leukoreduced platelet concentrates from pooled buffy coats in a mixture of solutions for medical use
Chengyin HUANG ; Li CAI ; Jianyu XIAO
Chinese Journal of Blood Transfusion 2008;0(09):-
Objective To develop a method to produce leukoreduced platelet concentrates(LR-PCs) from pooled buffy coats in additive solution(a mixture of solutions for medical use).Methods LR-PCs were made from 6 pooled buffy coats(12 whole-blood units) and 220g additive solution,including 90% multiple electrolytes injection solution,8% ACD-A and 2% 50g/L NaHCO3 injection solution.After centrifugation,the PCs were leukoreduced with a filter and stored in a 600ml platelet storage bag.LR-PCs were prepared in a closed system.Results Routinely produced LR-PCs(n=30) contained(2.96?0.31)?1011 platelets with a volume of(270? 32)ml.The WBC and RBC count were(1.3?0.2)?106 and(5.8?1.1)?109 per unit,respectively.The CD62P expression was(22.5? 10.6)%.After 8-day storage,the in vitro quality of LR-PCs,including pH,hypotonic shock response(HSR) and CD62P expression were 7.14?0.04,(54.0?8.2)% and(45.7?13.8)%,respectively.Conclusion In terms of the in vitro quality of LR-PCs,the method of preparing LR-PCs from pooled buffy coats in mixing solutions is feasible.
3.Identification of a Bw14 subtype and exploration for its molecular basis.
Qing CHEN ; Ping LI ; Jianyu XIAO ; Le LU ; Yan YE ; Shuya WANG ; Chengyin HUANG ; Yunlong ZHUANG
Chinese Journal of Medical Genetics 2017;34(5):755-758
OBJECTIVETo identify a rare subtype of the ABO blood group system and explore its molecular basis.
METHODSBased on a standard serological assay, ABO subtype and haplotype were analyzed through PCR amplification of the 7 exons and adjacent introns of the ABO gene and TA clone sequencing.
RESULTSForward typing showed a B type, while reverse typing demonstrated an extremely weak anti-B on routine gel analysis, which indicated a forward and reverse typing discrepancy. Absorption-elution testing confirmed that there was no A antigen on the surface of patient's red blood cells. Sequencing of the ABO gene showed a G>A exchange at position 523 in exon 7, which resulted in a Val to Met substitution at codon 175. Clone sequencing of the amplificons of the ABO gene showed an ABO* Bw14/O01 heterozygote genotype.
CONCLUSIONMolecular method is useful for the identification of ambiguous blood groups. A 523G>A substitution of the ABO gene resulting in a Bw14 subtype probably underlies the weak B phenotype noted in the patient.
ABO Blood-Group System ; genetics ; Exons ; Genotype ; Humans ; Male ; Middle Aged ; Phenotype ; Polymerase Chain Reaction
4.Development and validation of a liquid chromatography-isotope dilution tandem mass spectrometry for determination of olanzapine in human plasma and its application to bioavailability study.
Mengqi ZHANG ; Jingying JIA ; Chuan LU ; Gangyi LIU ; Chengyin YU ; Yuzhou GUI ; Yun LIU ; Yanmei LIU ; Wei WANG ; Shuijun LI ; Chen YU
Acta Pharmaceutica Sinica 2010;45(6):767-71
A simple, reliable and sensitive liquid chromatography-isotope dilution mass spectrometry (LC-ID/MS) was developed and validated for quantification of olanzapine in human plasma. Plasma samples (50 microL) were extracted with tert-butyl methyl ether and isotope-labeled internal standard (olanzapine-D3) was used. The chromatographic separation was performed on XBridge Shield RP 18 (100 mm x 2.1 mm, 3.5 microm, Waters). An isocratic program was used at a flow rate of 0.4 m x min(-1) with mobile phase consisting of acetonitrile and ammonium buffer (pH 8). The protonated ions of analytes were detected in positive ionization by multiple reactions monitoring (MRM) mode. The plasma method, with a lower limit of quantification (LLOQ) of 0.1 ng x mL(-1), demonstrated good linearity over a range of 0.1 - 30 ng x mL(-1) of olanzapine. Specificity, linearity, accuracy, precision, recovery, matrix effect and stability were evaluated during method validation. The validated method was successfully applied to analyzing human plasma samples in bioavailability study.
5.Molecular mechanisms underlying DEL phenotype among ethnic Han individuals from Jiangsu.
Qing CHEN ; Sisi WANG ; Jianyu XIAO ; Ping LI ; Chengyin HUANG ; Genhong YAO
Chinese Journal of Medical Genetics 2016;33(2):240-243
OBJECTIVETo explore the molecular mechanism underlying the DEL phenotype among RhD negative ethnic Han individuals from Jiangsu, China.
METHODSThe DEL phenotype was determined by an adsorption elution test among 57 RhD negative blood donors. The Rh C, c, E, and e phenotypes were detected by a tube method. PCR with sequence-specific primering (PCR-SSP) assay was used to determine the RHCE genotypes. The RHD gene of the DEL individuals were amplified with polymerase chain reaction and subjected to Sanger sequencing analysis.
RESULTSAmong the 57 RhD negative donors, 10 (17.54%) were determined as having the DEL phenotype. The major RhCE phenotypes for DEL and RhD negative cases were RhCcee (80.0%) and Rhccee (61.7%), respectively. All RHD gene sequences of the 10 individuals have harbored a G>A mutation at position 1227 of exon 9.
CONCLUSIONA proportion of RhD negative individuals determined by routine serological method are actually DEL with RHD gene mutations. RHD *1227A is the most prevalent DEL genotype among ethnic Han Chinese from Jiangsu. Further research on the phenotype and underlying molecular mechanism of DEL is important for blood transfusion.
Alleles ; Asian Continental Ancestry Group ; ethnology ; genetics ; Base Sequence ; Blood Donors ; China ; ethnology ; Exons ; Genotype ; Humans ; Male ; Molecular Sequence Data ; Phenotype ; Polymorphism, Genetic ; Rh-Hr Blood-Group System ; genetics
6.Investigation of ABO allelic competition phenomena in a pedigree with Bw11 subtype.
Chenchen FENG ; Weichao REN ; Daosheng CHENG ; Jingyan GAO ; Jianyong CHEN ; Weichao LI ; Jianyu XIAO ; Taixiang LIU ; Chengyin HUANG ; Qing CHEN
Chinese Journal of Medical Genetics 2021;38(1):23-26
OBJECTIVE:
To investigate the serological and molecular characteristics of a pedigree carrying an allele for ABO*BW.11 blood subgroup.
METHODS:
The ABO blood type of 9 pedigree members were determined by serological methods. Exons 6 and 7 of the ABO gene were amplified by PCR and directly sequenced. The patient and her father were also subjected to clone sequencing analysis.
RESULTS:
Serological tests demonstrated that the proband and her younger brother had an ABw subtype, whilst her father and two daughters had Bw subtype. Clone sequencing found that the exon 7 of the ABO gene of the proband had a T>C substitution at position 695, which was identified as a BW.11 allele compared with the reference sequence B.01. This BW.11 allele was also identified in the proband's father, brother and two daughters. Due to allelic competition, the A/BW.11 and BW.11/O alleles demonstrated significantly different phenotypes.
CONCLUSION
The c.695T>C substitution of the ABO gene may lead to allelic competition in the Bw11 subtype. Combined molecular and serological methods is helpful for precise blood grouping.
ABO Blood-Group System/genetics*
;
Alleles
;
Female
;
Genotype
;
Humans
;
Male
;
Pedigree
;
Phenotype
7.ABO sequence analysis in an AB type with anti-B patient.
Qing CHEN ; Jianyu XIAO ; Shuya WANG ; Jiahuang LI ; Leilei DU ; Le LU ; Chengyin HUANG ; Min LI ; Ping LI
Chinese Medical Journal 2014;127(5):971-972
ABO Blood-Group System
;
genetics
;
Exons
;
genetics
;
Female
;
Genotype
;
Humans
;
Middle Aged
8.Analysis of volatile organic compounds in exhaled breath after radiotherapy.
Dianlong GE ; Xue ZOU ; Yajing CHU ; Jijuan ZHOU ; Wei XU ; Yue LIU ; Qiangling ZHANG ; Yan LU ; Lei XIA ; Aiyue LI ; Chaoqun HUANG ; Pei WANG ; Chengyin SHEN ; Yannan CHU
Journal of Zhejiang University. Science. B 2022;23(2):153-157
Radiotherapy uses high-energy X-rays or other particles to destroy cancer cells and medical practitioners have used this approach extensively for cancer treatment (Hachadorian et al., 2020). However, it is accompanied by risks because it seriously harms normal cells while killing cancer cells. The side effects can lower cancer patients' quality of life and are very unpredictable due to individual differences (Bentzen, 2006). Therefore, it is essential to assess a patient's body damage after radiotherapy to formulate an individualized recovery treatment plan. Exhaled volatile organic compounds (VOCs) can be changed by radiotherapy and thus used for medical diagnosis (Vaks et al., 2012). During treatment, high-energy X-rays can induce apoptosis; meanwhile, cell membranes are damaged due to lipid peroxidation, converting unsaturated fatty acids into volatile metabolites (Losada-Barreiro and Bravo-Díaz, 2017). At the same time, radiotherapy oxidizes water, resulting in reactive oxygen species (ROS) that can increase the epithelial permeability of pulmonary alveoli, enabling the respiratory system to exhale volatile metabolites (Davidovich et al., 2013; Popa et al., 2020). These exhaled VOCs can be used to monitor body damage caused by radiotherapy.
Breath Tests/methods*
;
Exhalation
;
Humans
;
Quality of Life
;
Respiratory System/chemistry*
;
Volatile Organic Compounds/analysis*